drugset
drugset / Trial / NCT00309907

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

NCT00309907 ↗

Phase 2 Completed 39 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant. Etanercept may be effective in treating patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.

Timeline

Start
2006-04
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 0.4 mg/kg Intravenous
Background Methylprednisolone Other / unclassified 1 mg/kg Intravenous

Indications

Burkitt lymphoma Hodgkins lymphoma blast phase chronic myelogenous leukemia, BCR-ABL1 positive childhood acute lymphoblastic leukemia childhood acute myeloid leukemia childhood kidney neoplasm childhood myelodysplastic syndrome juvenile myelomonocytic leukemia leukemia, myeloid, accelerated-phase neuroblastoma rhabdomyosarcoma